Exendin-4 reduces glycemia by increasing liver glucokinase activity: an insulin independent effect. (Q54511441)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22580530%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

title

Exendin-4 reduces glycemia by increasing liver glucokinase activity: an insulin independent effect (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22580530%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22580530%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Gaurang Shah

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22580530%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

author name string

Nirav Dhanesha

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22580530%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Amit Joharapurkar

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22580530%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Vipin Dhote

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22580530%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Samadhan Kshirsagar

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22580530%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Rajesh Bahekar

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22580530%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Mukul Jain

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22580530%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

publication date

1 January 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22580530%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

published in

Pharmacological Reports

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22580530%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

volume

64

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22580530%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22580530%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

page(s)

140-149

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22580530%20AND%20SRC:MED&resulttype=core&format=json

Cell signalling of glucagon-like peptide-1 action in rat skeletal muscle.

1 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

Exendin-4 agonist and exendin(9-39)amide antagonist of the GLP-1(7-36)amide effects in liver and muscle

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

Effect of exendin-4 treatment upon glucose uptake parameters in rat liver and muscle, in normal and type 2 diabetic state.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

Exendin-4 promotes liver cell proliferation and enhances the PDX-1-induced liver to pancreas transdifferentiation process.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

Insulin sensitivity of suppression of endogenous glucose production is the single most important determinant of glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

High-yield preparation of isolated rat liver parenchymal cells: a biochemical and fine structural study

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

Early hepatic insulin resistance precedes the onset of diabetes in obese C57BLKS-db/db mice

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

Insulin resistance and diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

The biology of incretin hormones

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

Effects of glucagon-like peptide-1 (7-36)amide on insulin stimulated rat skeletal muscle glucose transport

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

Exenatide can reduce glucose independent of islet hormones or gastric emptying

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

Relationship between hepatic glucose production and fasting plasma glucose concentration in patients with NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

Metformin has adenosine-monophosphate activated protein kinase (AMPK)-independent effects on LPS-stimulated rat primary microglial cultures.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

GLP-1 does not acutely affect insulin sensitivity in healthy man

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

Direct enzymatic procedure for the determination of liver glycogen

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

Effects of glucagon-like peptide 1 (7-36 amide) on glucose kinetics during somatostatin-induced suppression of insulin secretion in healthy men

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

Glucagon-like peptide 1: a potent glycogenic hormone

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970740-5

7 January 2021

10.1016/S1734-1140(12)70740-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22580530%20AND%20SRC:MED&resulttype=core&format=json

release_mi6zgfxn2bdvrnjdyo6cdtghma

1 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mi6zgfxn2bdvrnjdyo6cdtghma

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22580530%20AND%20SRC:MED&resulttype=core&format=json